1. Home
  2. BTAI vs ACCL Comparison

BTAI vs ACCL Comparison

Compare BTAI & ACCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • ACCL
  • Stock Information
  • Founded
  • BTAI 2017
  • ACCL 2009
  • Country
  • BTAI United States
  • ACCL Hong Kong
  • Employees
  • BTAI 37
  • ACCL N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • ACCL Professional Services
  • Sector
  • BTAI Health Care
  • ACCL Consumer Discretionary
  • Exchange
  • BTAI Nasdaq
  • ACCL Nasdaq
  • Market Cap
  • BTAI 41.8M
  • ACCL 57.8M
  • IPO Year
  • BTAI 2018
  • ACCL 2025
  • Fundamental
  • Price
  • BTAI $2.12
  • ACCL $3.87
  • Analyst Decision
  • BTAI Buy
  • ACCL
  • Analyst Count
  • BTAI 5
  • ACCL 0
  • Target Price
  • BTAI $32.80
  • ACCL N/A
  • AVG Volume (30 Days)
  • BTAI 691.3K
  • ACCL 114.8K
  • Earning Date
  • BTAI 11-12-2025
  • ACCL 12-09-2025
  • Dividend Yield
  • BTAI N/A
  • ACCL N/A
  • EPS Growth
  • BTAI N/A
  • ACCL 2.91
  • EPS
  • BTAI N/A
  • ACCL 0.08
  • Revenue
  • BTAI $752,000.00
  • ACCL $4,888,824.00
  • Revenue This Year
  • BTAI N/A
  • ACCL N/A
  • Revenue Next Year
  • BTAI $544.99
  • ACCL N/A
  • P/E Ratio
  • BTAI N/A
  • ACCL $55.18
  • Revenue Growth
  • BTAI N/A
  • ACCL 11.91
  • 52 Week Low
  • BTAI $1.17
  • ACCL $2.10
  • 52 Week High
  • BTAI $9.26
  • ACCL $5.00
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 54.12
  • ACCL N/A
  • Support Level
  • BTAI $1.72
  • ACCL N/A
  • Resistance Level
  • BTAI $2.09
  • ACCL N/A
  • Average True Range (ATR)
  • BTAI 0.18
  • ACCL 0.00
  • MACD
  • BTAI 0.06
  • ACCL 0.00
  • Stochastic Oscillator
  • BTAI 98.36
  • ACCL 0.00

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About ACCL Acco Group Holdings Limited Ordinary Shares

Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.

Share on Social Networks: